Boehringer Ingelheim Pharmaceuticals, Inc.

181 articles with Boehringer Ingelheim Pharmaceuticals, Inc.

• 

  Boehringer, MiNA Therapeutics Forge EUR 307M R&D NASH Tie-Up

  11/8/2017

  Fresh off the heels of a $201M liver disease R&D deal with Dicerna, Boehringer Ingelheim  has struck another deal targeting liver disease with MiNA Therapeutics.

• Boehringer Ingelheim's Efficacy and Safety Maintained in Patients Who Switched From Humira to Biosimilar Cyltezo

  11/7/2017

  The 48-week data showed that Cyltezo is equivalent, with no clinically meaningful differences in efficacy, safety and immunogenicity to Humira in people with moderately-to-severely active RA, including in patients who switched from Humira to Cyltezo at week 24.

• Boehringer Ingelheim Release: Efficacy and Safety Maintained in Patients Who Switched From Humira to Biosimilar Cyltezo

  11/6/2017

  Boehringer Ingelheim today announced one-year data from VOLTAIRE-RA, a pivotal Phase III clinical trial comparing Cyltezo and reference product Humira.

• Boehringer Ingelheim Expands Collaboration With Sarah Cannon Research Institute to Investigate Novel Immuno-Oncology Combination Therapy

  10/30/2017

  Boehringer Ingelheim and Sarah Cannon Research Institute today announced an expansion of their strategic partnership which combines Boehringer Ingelheim's oncology research and Sarah Cannon's expertise in clinical trial design.

• Boehringer Ingelheim Release: Ofev Demonstrates Consistent Long-Term Efficacy in IPF Regardless of Baseline Lung Function

  10/23/2017

  Boehringer Ingelheim announced today the presentation of a new analysis on the use of Ofev (nintedanib) in treating people with idiopathic pulmonary fibrosis (IPF) at the 2017 CHEST Annual Meeting.

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: Results from The INJOURNEY Trial Investigating Ofev With Add-On Pirfenidone Provide New Insights Into This Combination Treatment For IPF

  9/11/2017

• Boehringer Ingelheim Pharmaceuticals, Inc. Receives FDA Approval For Cyltezo (Adalimumab-Adbm), A Biosimilar To Humira, For The Treatment Of Multiple Chronic Inflammatory Diseases

  8/29/2017

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Support Program Provides Free Medicine And Resources For People Living With COPD Prescribed STIOLTO RESPIMAT (Tiotropium Bromide And Olodaterol) Inhalation Spray

  10/12/2016

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Analysis Of INPULSIS Trials Demonstrates Efficacy Of OFEV (Nintedanib) Across A Range Of IPF Patients Using Broader Diagnostic Criteria

  6/27/2016

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: : Interim Phase III Data Show Praxbind (idarucizumab) Reverses Dabigatran (Pradaxa) In Emergency Situations

  4/4/2016

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Analysis Confirms OFEV (nintedanib) Slows Disease Progression In IPF And Reduces Risk Of Acute Exacerbations

  2/25/2016

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: Country Music Artist Joe Nichols Raises Awareness of Rare Lung Disease That Claimed His Father's Life and Leaves Those Affected "Breathless"

  2/18/2016

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: Newly Published Head-to-Head Data Show STIOLTO RESPIMAT Improved Lung Function Across Range Of Measures

  2/9/2016

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Published Data Show STIOLTO RESPIMAT Provides Clinically Meaningful Improvements In COPD Health-Related Quality Of Life Measure

  8/18/2015

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: STIOLTO RESPIMAT Now Available In The United States For The Treatment Of COPD

  6/30/2015

• Boehringer Ingelheim Pharmaceuticals, Inc. And Sutter Health Establish Research Collaboration To Improve Patient Care

  5/11/2015

• Pradaxa Maker Boehringer Ingelheim Pharmaceuticals, Inc. Pursues Pradaxa FDA Approval To Treat DVT And PE

  4/21/2015

• Boehringer Ingelheim Pharmaceuticals, Inc.'s Investigational Biologic Cleared Skin Better Than Ustekinumab In Head-To-Head Phase II Psoriasis Study

  3/20/2015

• New Data From Boehringer Ingelheim Pharmaceuticals, Inc.'s GLORIA-AF Registry Show Non-Valvular Atrial Fibrillation (NVAF) Patients At High Risk Of Stroke May Be Undertreated

  3/16/2015

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Survey Uncovers Emotional And Physical Impact Of Idiopathic Pulmonary Fibrosis, A Fatal Lung Disease

  2/12/2015